STATEMENT OF NEED
Approximately 37 million people in the United States are estimated to have chronic kidney disease (CKD), a condition in which the kidneys are unable to filter blood properly, leading to the accumulation of waste and excess fluid in the body. Patients may experience heart disease, stroke, anemia, and infections, along with the risk of kidney failure and the need for dialysis or kidney transplant if the disease is left untreated and progresses to end-stage renal disease (ESRD). In addition to significant health-related consequences, patients with CKD may face substantial financial toxicity. In 2019, overall Medicare costs for patients with CKD reached $87.2 billion, equating to $24,453 per Medicare beneficiary over 65 years old. For patients with kidney failure or ESRD, Medicare fee-for-service spending, including prescription drugs, totaled $37.3 billion, or $86,400 per person (CDC, 2022). To optimize the treatment and care of patients with CKD, it is vital to not only understand the efficacy and safety of novel therapies for slowing kidney function decline, but also to utilize approaches that maximize collaboration between payers and providers. In Module 1 of this activity, Jeff Sperry, PharmD, BCPS, Clinical Pharmacist at UCHealth Memorial Hospital, will explore risk factors contributing to CKD, efficacy and safety of novel therapies for slowing kidney function decline, and evidence-based strategies for management of CKD complications.
TARGET AUDIENCE
Managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, pharmacists, and other health care professionals involved in the case management of patients with chronic kidney disease (CKD).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Identify risk factors that contribute to CKD
- Appraise the efficacy and safety of novel therapies indicated to slow kidney function decline
- Evaluate evidence-based strategies for the management of common CKD complications
REGISTRATION
There is no fee to participate in or claim CPE credit for this activity.
PROVIDED BY
Continuing Pharmacy Education
St. John Fisher University Wegmans School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. UAN #0584-9999-23-028-H01-P is eligible for 1.5 ACPE CE hours upon competion of both modules.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) endorse the standards of the ACPE that require everyone in a position to control the content of a CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CPE activity. CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
St. John Fisher University Wegmans School of Pharmacy (WSOP) staff members have no relevant financial relationships to disclose.
Jeff Sperry, PharmD, BCPS, has no relevant financial relationships to disclose.
Justin J. Bioc, PharmD, BCPS, BCGP, RPh, has no relevant financial relationships to disclose.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.
TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES
For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:
- The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
- The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
COMMERCIAL SUPPORT
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.
STATEMENT OF NEED
Approximately 37 million people in the United States are estimated to have chronic kidney disease (CKD), a condition in which the kidneys are unable to filter blood properly, leading to the accumulation of waste and excess fluid in the body. Patients may experience heart disease, stroke, anemia, and infections, along with the risk of kidney failure and the need for dialysis or kidney transplant if the disease is left untreated and progresses to end-stage renal disease (ESRD). In addition to significant health-related consequences, patients with CKD may face substantial financial toxicity. In 2019, overall Medicare costs for patients with CKD reached $87.2 billion, equating to $24,453 per Medicare beneficiary over 65 years old. For patients with kidney failure or ESRD, Medicare fee-for-service spending, including prescription drugs, totaled $37.3 billion, or $86,400 per person (CDC, 2022). To optimize the treatment and care of patients with CKD, it is vital to not only understand the efficacy and safety of novel therapies for slowing kidney function decline, but also to utilize approaches that maximize collaboration between payers and providers. In this activity, Justin J. Bioc, PharmD, BCPS, BCGP, RPh, Head of Clinical Pharmacy at Devoted Health, will explore the cost-effectiveness of novel therapies indicated to slow kidney function decline and strategies that maximize collaboration between payers and providers to optimize the care of patients with CKD.
TARGET AUDIENCE
Managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, pharmacists, and other health care professionals involved in the case management of patients with chronic kidney disease (CKD).
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Compare the cost effectiveness of novel therapies indicated to slow kidney function decline
- Utilize strategies that maximize collaboration between payers and providers to optimize the care of patients with CKD
REGISTRATION
There is no fee to participate in or claim CPE credit for this activity.
PROVIDED BY
Continuing Pharmacy Education
St. John Fisher University Wegmans School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. UAN #0584-9999-23-028-H01-P is eligible for 1.5 ACPE CE hours upon competion of both modules.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) endorse the standards of the ACPE that require everyone in a position to control the content of a CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CPE activity. CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in health care. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when an individual has an opportunity to affect CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.
i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health and St. John Fisher University Wegmans School of Pharmacy (WSOP) does not endorse any products or services.
Relevant financial relationships exist between the following individuals and ineligible companies:
The i3 Health planners, reviewers, and managers have nothing to disclose.
St. John Fisher University Wegmans School of Pharmacy (WSOP) staff members have no relevant financial relationships to disclose.
Jeff Sperry, PharmD, BCPS, has no relevant financial relationships to disclose.
Justin J. Bioc, PharmD, BCPS, BCGP, RPh, has no relevant financial relationships to disclose.
i3 Health has mitigated all relevant financial relationships.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must attend the scheduled activity and submit a completed evaluation at the end of the activity.
TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES
For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:
- The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
- The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.
UNAPPROVED USE DISCLOSURE
i3 Health requires CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.
This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
DISCLAIMER
The information provided at this CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a health care provider relative to diagnostic and treatment options of a specific patient’s medical condition.
COMMERCIAL SUPPORT
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
CONTACT INFORMATION
Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.
FORMAT
Online Activity
CREDIT
1.5 ACPE Credits upon completion of both modules
ESTIMATED TIME TO COMPLETE
1 hour and 30 minutes
Module 1: 45 minutes
Module 2: 45 minutes
DATES AVAILABLE
December 21, 2023 - December 20, 2024
i3 Health is pleased to make the speaker slides available for use as a non-accredited self-study or teaching resource.
To download the infographic please click the link below.
